Kernaussagen
- 1Itemising the year revealed supportive care was ~30% of the total — and the easiest component to substitute generically.
- 2The centre already used biosimilar trastuzumab as standard; the family simply hadn't asked.
- 3Protocol never changed: no delayed cycles, no reduced doses — cost management operated entirely inside the clinical plan.
- 4A financial navigator, asked about at the second appointment instead of the tenth, was worth thousands in unclaimed support.
Fallüberblick
- Patientenprofil
- Composite profile — 44-year-old, HER2-positive early breast cancer
- Land
- Germany, treated privately for part of the pathway
- Erkrankung
- HER2-positive breast cancer, adjuvant therapy
- Medikament
- Trastuzumab, docetaxel, pegfilgrastim, zoledronic acid, ondansetron
Kosten im Westen
~$61,000 for 12 months
Referenzalternative
~$11,000 equivalent reference basket
Wirkung
~$50,000 across the treatment year
Auf dieser Seite
1The protocol, and what could not change
HER2-positive breast cancer is treated with targeted anti-HER2 therapy alongside chemotherapy, typically continuing for around twelve months in the adjuvant setting. The schedule is evidence-based and dose intensity matters.
The first principle established with her oncologist was that the protocol itself was not negotiable. No delayed cycles, no reduced doses, no omitted supportive medicines. Cost management had to operate entirely inside the clinical plan.
2Where the cost actually sat
Itemising the year revealed something the family had not expected: supportive care was almost a third of the total. Growth-factor support, bone-protective therapy and anti-emetics together approached the cost of the chemotherapy agent itself.
| Component | Originator basis | Biosimilar / generic basis | Reduction |
|---|---|---|---|
| Trastuzumab (year of therapy) | ~$34,000 | ~$6,200 | 82% |
| Docetaxel (6 cycles) | ~$5,800 | ~$260 | 96% |
| Pegfilgrastim (6 doses) | ~$37,200 | ~$660 | 98% |
| Zoledronic acid (12 doses) | ~$7,400 | ~$220 | 97% |
| Ondansetron and anti-emetics | ~$1,900 | ~$140 | 93% |
3The decisions taken
Her oncology centre already used biosimilar trastuzumab as standard, which she had not realised. The remaining changes were made to supportive care, where generic equivalents were straightforward.
- 1Confirmed the centre's biosimilar trastuzumab policy and the specific product used.
- 2Switched growth-factor support to a generic equivalent with the oncologist's agreement.
- 3Moved bone-protective therapy to generic zoledronic acid.
- 4Switched anti-emetics to generic ondansetron and generic aprepitant.
- 5Applied to a breast cancer charity for travel and accommodation support.
- 6Recorded product and batch numbers at every administration for pharmacovigilance.
4Outcome
She completed all planned cycles on schedule, with no delays attributable to cost. Cardiac monitoring during anti-HER2 therapy remained within acceptable limits, and the protocol finished as designed.
The financial navigator at her centre — a role she had not known existed until she asked — handled two of the charity applications. That single question, asked at the second appointment rather than the tenth, was worth several thousand dollars.
5About this case study
This is a composite case study. It illustrates a real, documented price pattern using a representative patient profile rather than a specific identifiable individual. Figures are reference ranges, not quotations, and outcomes vary by person, dose and market.
Showing figures without a story leaves the real lesson out: these cases are about adherence that became possible again, monitoring that started up again, and rationing that stopped — not simply about a cheaper invoice.
Discuss any change of medicine, dose or brand with a licensed clinician before acting on anything on this page.
Jivan publishes pricing and educational information only. Do not start, stop, substitute or re-dose any medicine without a licensed physician's approval.
Was der Jivan-Datensatz zeigt
- 27.5×
- durchschnittliche Preislücke Oncology
- 89.2%
- der Anker übersteigt 10×
- 129×
- größte dokumentierte Lücke
Across our Oncology anchors, 83 referenced molecules average a 27.5× price gap, 89.2% of them are at least 10× cheaper in India, and the widest documented comparison is Thalidomide at 129×. Among Oncology anchors, supportive-care molecules (growth factors, bone agents) reach some of the highest percentage savings in the catalog — higher than many primary agents.
Live berechnet aus 83 anchors
Häufige Fragen
Regulators approve biosimilars only after a comparability programme demonstrates no clinically meaningful differences in quality, safety and efficacy. Many cancer centres use them as the default option.
Generic equivalents of anti-emetics, growth factors and bone agents are widely used. The decision belongs to the oncology team, but it is usually straightforward and is frequently the largest available saving.
A staff member at many cancer centres whose job is to connect patients with assistance programmes, charitable grants and hardship funds. Ask at your first or second appointment rather than waiting.
Quellen und weiterführende Literatur
Jede sachliche Aussage oben ist zu einer öffentlichen Primärquelle rückverfolgbar. Wir zitieren Regulierer und Gesundheitsbehörden, keine Händler.
- 1Biosimilar Medicines OverviewEuropean Medicines Agency
- 2Generic Drug FactsU.S. Food & Drug Administration
- 3WHO Model List of Essential MedicinesWorld Health Organization
- 4MedlinePlus Drug InformationU.S. National Library of Medicine
Wie dieser Artikel entstand
Geschrieben und recherchiert
Pricing Research Editor, Jivan Editorial TeamRedaktionell geprüft
Editorial Review Board — Jivan
Composite profile assembled from documented price patterns; not a named individual.
Wichtiger medizinischer Hinweis
Ändern Sie Medikament, Dosis oder Hersteller nur nach Rücksprache mit einer approbierten Ärztin oder einem approbierten Arzt. Jivan liefert Bildungs- und Preisinformationen und ersetzt keine Diagnose oder Notfallversorgung.